IL312382A - COMPOUNDS AND METHODS OF ORAL ADMINISTRATION - Google Patents
COMPOUNDS AND METHODS OF ORAL ADMINISTRATIONInfo
- Publication number
- IL312382A IL312382A IL312382A IL31238224A IL312382A IL 312382 A IL312382 A IL 312382A IL 312382 A IL312382 A IL 312382A IL 31238224 A IL31238224 A IL 31238224A IL 312382 A IL312382 A IL 312382A
- Authority
- IL
- Israel
- Prior art keywords
- polypeptide
- seq
- construct
- polypeptide construct
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Immunology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163288579P | 2021-12-11 | 2021-12-11 | |
| PCT/US2022/081277 WO2023108126A1 (en) | 2021-12-11 | 2022-12-09 | Compositions and methods for oral administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL312382A true IL312382A (en) | 2024-06-01 |
Family
ID=86731317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL312382A IL312382A (en) | 2021-12-11 | 2022-12-09 | COMPOUNDS AND METHODS OF ORAL ADMINISTRATION |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250388638A1 (https=) |
| EP (1) | EP4444352A4 (https=) |
| JP (1) | JP2024545981A (https=) |
| KR (1) | KR20240141165A (https=) |
| CN (1) | CN118613284A (https=) |
| AU (1) | AU2022405604A1 (https=) |
| CA (1) | CA3235948A1 (https=) |
| IL (1) | IL312382A (https=) |
| MX (1) | MX2024007105A (https=) |
| WO (1) | WO2023108126A1 (https=) |
| ZA (1) | ZA202404443B (https=) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| US20070042392A1 (en) * | 2000-02-03 | 2007-02-22 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
| KR100944034B1 (ko) * | 2007-04-19 | 2010-02-24 | 한올제약주식회사 | 프로테아제-내성 폴리펩티드의 경구 투여 제형 |
| KR102497242B1 (ko) * | 2016-11-13 | 2023-02-09 | 이매진 파마 | 당뇨병, 고혈압 및 고콜레스테롤혈증을 치료하기 위한 조성물 및 방법 |
| PL3746111T3 (pl) * | 2018-02-02 | 2024-01-15 | Novo Nordisk A/S | Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową |
-
2022
- 2022-12-09 IL IL312382A patent/IL312382A/en unknown
- 2022-12-09 CN CN202280074852.8A patent/CN118613284A/zh active Pending
- 2022-12-09 US US18/683,324 patent/US20250388638A1/en active Pending
- 2022-12-09 MX MX2024007105A patent/MX2024007105A/es unknown
- 2022-12-09 AU AU2022405604A patent/AU2022405604A1/en active Pending
- 2022-12-09 JP JP2023574593A patent/JP2024545981A/ja active Pending
- 2022-12-09 WO PCT/US2022/081277 patent/WO2023108126A1/en not_active Ceased
- 2022-12-09 EP EP22905413.5A patent/EP4444352A4/en active Pending
- 2022-12-09 CA CA3235948A patent/CA3235948A1/en active Pending
-
2023
- 2023-03-14 KR KR1020247023226A patent/KR20240141165A/ko active Pending
-
2024
- 2024-06-07 ZA ZA2024/04443A patent/ZA202404443B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023108126A9 (en) | 2023-08-24 |
| CA3235948A1 (en) | 2023-06-15 |
| MX2024007105A (es) | 2024-06-24 |
| EP4444352A4 (en) | 2025-12-17 |
| KR20240141165A (ko) | 2024-09-25 |
| WO2023108126A1 (en) | 2023-06-15 |
| AU2022405604A2 (en) | 2024-07-11 |
| JP2024545981A (ja) | 2024-12-17 |
| ZA202404443B (en) | 2025-10-29 |
| US20250388638A1 (en) | 2025-12-25 |
| AU2022405604A1 (en) | 2024-06-13 |
| CN118613284A (zh) | 2024-09-06 |
| EP4444352A1 (en) | 2024-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9074015B2 (en) | Recombinantly expressed insulin polypeptides and uses thereof | |
| CN101389650B (zh) | 包含酰化胰岛素和锌的组合物以及制备所述组合物的方法 | |
| JP5749155B2 (ja) | プロテアーゼ安定化アシル化インスリンアナログ | |
| US20100261637A1 (en) | Peptides derivatized with a-b-c-d- and their therapeutical use | |
| EP3808369B1 (en) | Use of il-22 dimers in manufacture of a medicament for intravenous administration | |
| JP2003160598A (ja) | 接合安定化されたポリペプチド組成物 | |
| CN105121459A (zh) | 通过连接至促性腺激素羧基端肽来增加多肽的流体动力学体积的方法 | |
| EP4013395A1 (en) | Compositions and particles for payload delivery | |
| Lee et al. | Genetic engineering of novel super long-acting Exendin-4 chimeric protein for effective treatment of metabolic and cognitive complications of obesity | |
| US20250099599A1 (en) | Furin-cleavable delivery constructs | |
| EP3442562B1 (en) | An il-22 dimer for use in treating necrotizing enterocolitis | |
| WO2021037187A1 (zh) | 一种多肽及其应用 | |
| US20250388638A1 (en) | Compositions and methods for oral delivery | |
| CN105142660A (zh) | N末端截短的胰岛素类似物 | |
| AU2005265266A1 (en) | Aequorin-containing compositions and methods of using same | |
| HK40109249A (zh) | 用於口服给予的组合物和方法 | |
| TW202535451A (zh) | 經修飾之調酸素及其使用方法 | |
| WO2025117857A2 (en) | Adp-ribosylation factor compositions and methods of use thereof | |
| KR20170069997A (ko) | 미리스토일화된 렙틴-관련된 펩티드 및 이들의 용도 | |
| HK40070502B (zh) | 胰岛素衍生物 | |
| NZ622174A (en) | Glucagon-like peptide-2 compositions and methods of making and using same | |
| JPWO2023108126A5 (https=) | ||
| HK40002973A (en) | An il-22 dimer for use in treating necrotizing enterocolitis | |
| NZ622174B2 (en) | Glucagon-like peptide-2 compositions and methods of making and using same |